Molecule specifically acting in a tissue where a cell death being observed
OwnerJun Zhi ER, Tomoyuki IGAWAinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a molecule which binds to a component or a portion thereof of a cell which is exposed to a extracellular environment due to a cell death (e.g. a filament or a histone which forms a cytoskeleton or a nuclear skeleton), which is observed specifically in an affected tissue, and concurrently binds to a target molecule on or in a cell, which acts specifically in a tissue where a cell death is observed such as affected tissue, abnormal tissue or the like. The molecule of the present invention is useful for a medicament with reduced adverse effect while conferring significant therapeutic or preventive effect.
Claims130
An antigen-binding molecule which comprises:
- (1) at least one first moiety that binds to a first antigen, and
- (2) at least one second moiety that binds to a second antigen;
- wherein said first antigen is a damage-associated molecular pattern (DAMP), and
- wherein said second antigen is different from the first antigen,
- preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the first antigen is selected from the group consisting of:
- a) Splicing Factor 3B Subunit 3 (SF3B3);
- and
- b) Proliferating Cell Nuclear Antigen (PCNA).
A method of screening an antigen-binding molecule, which comprises the steps of:
- (a) selecting one or more nucleic acid(s) encoding at least one first moiety wherein the first moiety binds to a first antigen, and wherein the first antigen is a damage-associated molecular pattern (DAMP), wherein the first antigen is selected from the group consisting of:
- a) Splicing Factor 3B Subunit 3 (SF3B3);
- and b) Proliferating Cell Nuclear Antigen (PCNA);
- (b) selecting one or more nucleic acid(s) encoding at least one second moiety wherein the second moiety binds to a second antigen, and wherein the second antigen is different from the first antigen, preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell;
- (b1) optionally providing one or more nucleic acid(s) encoding at least one third moiety wherein the third moiety binds to a third antigen, wherein the third antigen is different from the first antigen, preferably wherein said third antigen is a membrane protein of an immune cell, or a tumour cell;
- (c) obtaining one or more nucleic acid(s) encoding an antigen-binding molecule wherein the at least one first moiety provided in (a) and the at least one second moiety provided in (b) and optionally the at least one third moiety provided in (b1) is/are linked;
- and
- (d) producing the antigen-binding molecule using the one or more nucleic acid(s) prepared in (c), thereby obtaining the antigen-binding molecule.
A method of producing an antigen-binding molecule, which comprises the steps of:
- (a) providing one or more nucleic acid(s) encoding at least one first moiety wherein the first moiety binds to a first antigen, and wherein the first antigen is a damage-associated molecular pattern (DAMP), wherein the first antigen is selected from the group consisting of:
- a) Splicing Factor 3B Subunit 3 (SF3B3);
- and b) Proliferating Cell Nuclear Antigen (PCNA);
- (b) providing one or more nucleic acid(s) encoding at least one second moiety wherein the second moiety binds to a second antigen and wherein the second antigen is different from the first antigen, preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell
- (b1) optionally providing one or more nucleic acid(s) encoding at least one third moiety wherein the third moiety binds to a third antigen, wherein the third antigen is different from the first antigen, preferably wherein said third antigen is a membrane protein of an immune cell, or a tumour cell;
- (c) obtaining one or more nucleic acid(s) encoding an antigen-binding molecule wherein the at least one first moiety provided in (a) and the at least one second moiety provided in (b) and optionally the at least one third moiety provided in (b1) is/are linked;
- and
- (d) producing the antigen-binding molecule using the one or more nucleic acid(s) prepared in (c) thereby obtaining the antigen-binding molecule.
A method of conferring a signal transmission or blockage in a cell comprising contacting an antigen-binding molecule with a cell, or comprising administering to a subject an antigen-binding molecule, wherein the antigen-binding molecule comprises:
- (1) at least one first moiety that binds to a first antigen, and
- (2) at least one second moiety that binds to a second antigen;
- wherein said first antigen is a damage-associated molecular pattern (DAMP), and
- wherein said second antigen is different from the first antigen,
- preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the first antigen is selected from the group consisting of:
- a) Splicing Factor 3B Subunit 3 (SF3B3);
- and
- b) Proliferating Cell Nuclear Antigen (PCNA).
A method of activating or preventing an immune response comprising contacting an antigen-binding molecule with a cell, or comprising administering to a subject an antigen-binding molecule, wherein the antigen binding molecule comprises:
- (1) at least one first moiety that binds to a first antigen, and
- (2) at least one second moiety that binds to a second antigen;
- wherein said first antigen is a damage-associated molecular pattern (DAMP), and
- wherein said second antigen is different from the first antigen,
- preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the first antigen is selected from the group consisting of:
- a) Splicing Factor 3B Subunit 3 (SF3B3);
- and
- b) Proliferating Cell Nuclear Antigen (PCNA).
A bispecific anti-Phosphatidylserine (PS) anti-CD3 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Phosphatidylserine (PS) anti-CD3 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Phosphatidylserine (PS) anti-CD3 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Phosphatidylserine (PS) anti-CD3 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Phosphatidylserine (PS) anti-CD137 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Phosphatidylserine (PS) anti-CD137 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Phosphatidylserine (PS) anti-CD137 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Phosphatidylserine (PS) anti-CD137 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD3 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD3 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD3 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD3 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD137 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD137 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD137 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-F-Actin anti-CD137 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec9A polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD3 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD3 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD3 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD3 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD137 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD137 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD137 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Splicing Factor 3B Subunit 3 (SF3B3) anti-CD137 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
The bispecific molecule or pharmaceutical composition of claim89 for use in a method of treating or preventing a cancer disease, preferably wherein the cancer disease is a solid tumour.
A bispecific antigen-binding molecule which is an anti-CD3 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific antigen-binding molecule which is an anti-CD137 antibody comprising a Clec4e polypeptide, wherein the molecule is an IgG type antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antigen-binding molecule and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD3 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD3 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD3 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD3 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD137 antibody comprising a heavy chain of IgG1 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD137 antibody comprising a heavy chain of IgG2 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD137 antibody comprising a heavy chain of IgG3 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
A bispecific anti-Proliferating Cell Nuclear Antigen (PCNA) anti-CD137 antibody comprising a heavy chain of IgG4 isotype and a light chain of kappa isotype or of lambda isotype, or a pharmaceutical composition comprising the bispecific antibody and one or more pharmaceutically acceptable carriers.
An antigen-binding molecule which comprises:
- (1) at least one first moiety that binds to a first antigen, and
- (2) at least one second moiety that binds to a second antigen;
- wherein said first antigen is a damage-associated molecular pattern (DAMP), and wherein said second antigen is different from the first antigen,
- preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the molecule comprises at least one third moiety that binds to a third antigen;
- wherein said third antigen is different from the first antigen;
- preferably wherein said third antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the first antigen is selected from the group consisting of:
- a) F-actin;
- b) Phosphatidylserine (PS);
- c) Splicing Factor 3B Subunit 3 (SF3B3);
- and
- d) Proliferating Cell Nuclear Antigen (PCNA).
A method of screening an antigen-binding molecule, which comprises the steps of:
- (a) selecting one or more nucleic acid(s) encoding at least one first moiety wherein the first moiety binds to a first antigen, and wherein the first antigen is a damage-associated molecular pattern (DAMP), wherein the first antigen is selected from the group consisting of:
- a) F-actin;
- b) Phosphatidylserine (PS);
- c) Splicing Factor 3B Subunit 3 (SF3B3);
- and d) Proliferating Cell Nuclear Antigen (PCNA);
- (b) selecting one or more nucleic acid(s) encoding at least one second moiety wherein the second moiety binds to a second antigen, and wherein the second antigen is different from the first antigen, preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell;
- (b1) providing one or more nucleic acid(s) encoding at least one third moiety wherein the third moiety binds to a third antigen, wherein the third antigen is different from the first antigen, preferably wherein said third antigen is a membrane protein of an immune cell, or a tumour cell;
- (c) obtaining one or more nucleic acid(s) encoding an antigen-binding molecule wherein the at least one first moiety provided in (a) and the at least one second moiety provided in (b) and the at least one third moiety provided in (b1) is/are linked;
- and
- (d) producing the antigen-binding molecule using the one or more nucleic acid(s) prepared in (c), thereby obtaining the antigen-binding molecule.
A method of producing of an antigen-binding molecule, which comprises the steps of:
- (a) providing one or more nucleic acid(s) encoding at least one first moiety wherein the first moiety binds to a first antigen, and wherein the first antigen is a damage-associated molecular pattern (DAMP);
- wherein the first antigen is selected from the group consisting of:
- a) F-actin;
- b) Phosphatidylserine (PS);
- c) Splicing Factor 3B Subunit 3 (SF3B3);
- and d) Proliferating Cell Nuclear Antigen (PCNA);
- (b) providing one or more nucleic acid(s) encoding at least one second moiety wherein the second moiety binds to a second antigen, and wherein the second antigen is different from the first antigen;
- preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell;
- (b1) providing one or more nucleic acid(s) encoding at least one third moiety wherein the third moiety binds to a third antigen, wherein the third antigen is different from the first antigen, preferably wherein said third antigen is a membrane protein of an immune cell, or a tumour cell;
- (c) obtaining one or more nucleic acid(s) encoding an antigen-binding molecule the at least one first moiety provided in (a) and the at least one second moiety provided in (b) and the at least one third moiety provided in (b1) is/are linked;
- and
- (d) producing the antigen-binding molecule using the one or more nucleic acid(s) prepared in (c) thereby obtaining the antigen-binding molecule.
A method of conferring a signal transmission or blockage in a cell comprising contacting an antigen-binding molecule with a cell, or comprising administering to a subject an antigen-binding molecule, wherein the antigen-binding molecule comprises:
- (1) at least one first moiety that binds to a first antigen, and
- (2) at least one second moiety that binds to a second antigen;
- wherein said first antigen is a damage-associated molecular pattern (DAMP), and wherein said second antigen is different from the first antigen,
- preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the molecule comprises at least one third moiety that binds to a third antigen;
- wherein said third antigen is different from the first antigen;
- preferably wherein said third antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the first antigen is selected from the group consisting of:
- a) F-actin;
- b) Phosphatidylserine (PS);
- c) Splicing Factor 3B Subunit 3 (SF3B3);
- and
- d) Proliferating Cell Nuclear Antigen (PCNA).
A method of activating or preventing an immune response comprising contacting an antigen-binding molecule with a cell, or comprising administering to a subject an antigen-binding molecule, wherein the antigen binding molecule comprises:
- (1) at least one first moiety that binds to a first antigen, and
- (2) at least one second moiety that binds to a second antigen;
- wherein said first antigen is a damage-associated molecular pattern (DAMP), and
- wherein said second antigen is different from the first antigen,
- preferably wherein said second antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the molecule comprises at least one third moiety that binds to a third antigen;
- wherein said third antigen is different from the first antigen;
- preferably wherein said third antigen is a membrane protein of an immune cell, or a tumour cell, and
- wherein the first antigen is selected from the group consisting of:
- a) F-actin;
- b) Phosphatidylserine (PS);
- c) Splicing Factor 3B Subunit 3 (SF3B3);
- and
- d) Proliferating Cell Nuclear Antigen (PCNA).
Dependencies are inferred from the claim text.